Medication info
Crezin Tablet 10mg (Rosuvastatin Calcium)

Crezin Tablet 10mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium Micronized›10.4mg / 1 tablet
Manufacturer / importer
IQURE Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201603369 · Approved 2016.06.10 · Insurance code 674401230

Summary

Main use
Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this medicine should follow a standard cholesterol-lowering diet before and during treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 milligrams daily. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
Ages 10 ~ 17 years: The usual dose range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Adjust the dose at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
IQURE Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medicine is used as an adjunct when diet and exercise alone do not suffice for patients with primary hypercholesterolemia and mixed dyslipidemia. It is also used as an adjunct for patients with rare homozygous familial hypercholesterolemia. This medication effectively lowers total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis and thereby reducing the risk of cardiovascular disease. It can be safely used as an adjunct to diet in certain high-risk groups of children aged 10 to 17. It is also beneficial for patients with primary dysbetalipoproteinemia, reducing the risk of cardiovascular events such as stroke, myocardial infarction, and recurrence after vascular revascularization. Overall, this medication is used effectively for improving blood lipids and preventing cardiovascular complications.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this medicine should follow a standard cholesterol-lowering diet before and during treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 milligrams daily. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

Ages 10 ~ 17 years: The usual dose range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Adjust the dose at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used in patients with an allergy to specific ingredients. It should not be administered to individuals with severely impaired liver function or persistently elevated liver enzyme levels of unknown cause. Patients with muscle diseases or previous muscle issues should not take this medication. It is contraindicated for patients taking cyclosporine. Patients with very poor kidney function, particularly those with a creatinine clearance of less than 30 mL/min, should not use this medication. Pregnant or breastfeeding women, as well as women of childbearing age who do not use adequate contraceptive methods, should not take this medication. Women with a potential for pregnancy can only use this medication if they are very unlikely to conceive and have been adequately informed about the risks to the fetus. High doses (40 mg) are contraindicated in patients at high risk of muscle-related diseases. Risk factors include moderate renal impairment, hypothyroidism, family history or genetic history of muscle disorders, previous myotoxicity with similar medications, alcohol dependency, increased plasma concentration scenarios, Asian patients, and co-administration with fibrate drugs. This medication contains lactose, thus should not be administered to patients with lactose intolerance or related genetic disorders. Before taking this medication, liver function tests should be repeated to assess liver status, and patients with a history of high alcohol consumption or liver disease should exercise caution. Patients with hypercholesterolemia due to hypothyroidism or nephrotic syndrome should treat the underlying disease before administering this medication. Muscle-related side effects, such as myalgia, myopathy, and, rarely, rhabdomyolysis can occur, necessitating immediate communication with healthcare providers if any muscle-related symptoms arise. If there is a significant increase in creatine kinase levels alongside muscle-related symptoms, this medication should be discontinued. Creatine kinase levels can also increase after intense exercise or for other reasons, making caution necessary during testing. In acute severe conditions or severe diseases, this medication should be discontinued, and if severe muscle weakness or ocular muscle weakness occurs, administration should cease immediately. The risk of muscle toxicity may increase with co-administration of other medications, especially with high doses of fibrate drugs. Regular kidney function tests are recommended for patients taking high doses of this medication. Asian patients may experience increased body exposure to the drug, requiring careful dose adjustment. In pediatric patients, monitoring for growth and pubertal development is necessary, and attention should be given to elevated muscle enzyme levels post-exercise. Mild and transient side effects have been reported, with common symptoms including headache, dizziness, abdominal pain, constipation, myalgia, weakness, diarrhea, chest pain, cough, fatigue, numbness, paresthesia, loss of appetite, abdominal bloating, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, joint pain, hematuria, thrombocytopenia, memory loss, peripheral neuropathy, polyneuropathy, depression, sleep disorders (including insomnia and nightmares), sexual dysfunction, gynecomastia, increased ALT, and AST.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, severe muscle weakness, cough, dyspnea, diarrhea, ocular muscle weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), lichenoid drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture, and it is best to keep it at room temperature between 1 to 30 degrees Celsius. This will help maintain the drug's efficacy and safety.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.